Asthma
Conditions
Keywords
Bronchial Thermoplasty
Brief summary
Patients in London and Hamilton with severe asthma who are deemed eligible by a respirologist to undergo bronchial thermoplasty treatment will be randomized to image-guided or conventional bronchial thermoplasty using hyperpolarized noble gas imaging.
Detailed description
This is a one year, single centre randomized controlled trial. Subjects will be identified through the London Asthma Centre located at St. Joseph's Hospital and from Hamilton at St. Joseph's Healthcare, and will be given a letter of information for the study. The study will only recruit subjects with asthma who are undergoing BT as part of their normal clinical care and asthma treatment plan. Those interested will sign the consent form at the clinic. Bronchial thermoplasty (BT) is a novel FDA approved outpatient asthma treatment procedure which aims to cure symptoms by permanently reducing airway smooth muscle mass in the lobar and segmental bronchi. Under local anesthetic, radiofrequency energy is delivered to warm the airway wall to 65 degrees celcius. The effect of this procedure is a reduction in airway smooth muscle mass in the treated airways resulting in a reduced potential for bronchoconstriction. Fourteen asthma patients will be enrolled in the study and each subject will visit the centre on five occasions (three pre-treatment visits and two post-treatment visits). We will evaluate pre-therapy optimization using inflammometry, pre-therapy ventilation defect reproducibility and BT treatment effects (pre-treatment visit 1= 5±2 days pre-optimization, pre-treatment visit 2 = 15±7 days pre-BT, pre-treatment visit 3 = 5±2 days pre-BT, post-treatment visit 4=6 weeks post-BT, post treatment visit 5 = 6 months post-BT). At pre-treatment visit 1, patients will be randomized to image-guided or conventional therapy. For all subjects, at all visits, spirometry, plethysmography and 3He and/or 129Xe MRI will be performed. Methacholine challenge (MCh) will be performed (for those subjects with FEV1 \>60%) at pre-treatment visit 3 and post-treatment visit 4 with spirometry and MRI performed pre- and post-MCh. Pre-treatment visit 3 will include a low-dose thoracic CT that will be used to generate a detailed 3D model of the airway tree. MRI will be co-registered to the CT with 3D airway rendering to enable spatial comparisons between ventilation defects and airways. All subjects will also complete bi-weekly and weekly quality of life questionnaires. Self-reported data will be uploaded by each subject monthly to our website using a confidential and password protected upload. MRI of the lungs will be performed using an inhaled contrast agent: either Hyperpolarized Helium-3 or Hyperpolarized Xenon-129. Participants will inhale the hyperpolarized gas and perform a breathhold for up to 16 seconds. Two different types of images will be acquired in the coronal plain during each visit: 1) 1H thoracic cavity, and 2) 3He and/or 129Xe static ventilation. Respiration and oxygen saturation will be monitored throughout the imaging session.
Interventions
PROCEDUREConventional Bronchial Thermoplasty
Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
PROCEDUREImage Guided Bronchial Thermoplasty
Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
Sponsors
McMaster University
Dr. Grace Parraga
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent * Male and female aged 18-60 years of age with a clinical diagnosis of asthma, as per: * Beta-agonist reversibility of FEV1\>12%, OR * Methacholine FEV1 PC20 ≤ 8 mg/ml if not receiving ICS or ≤ 16mg/ml if receiving an ICS. * Subject has asthma and is taking regular maintenance medication for the past 12 months that includes: * Inhaled corticosteroid (ICS) * Long-acting beta agonist (LABA) * Other asthma medication such as leukotriene modifier, or anti-IgE, are acceptable * FEV1 \> 50%pred pre-bronchodilator * Subject assigned by the clinical team to receive bronchial thermoplasty as part of their asthma treatment plan * Subject is a non-smoker for 1 year or greater (if former smoker less than 10 pack years total smoking history). * Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater.) * Subject is judged to be in otherwise stable health on the basis of medical history
Exclusion criteria
* Subject is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material * Subject is unable to perform spirometry or plethysmography maneuvers * Subject is pregnant * Recent (within 4 weeks of BL Visit 1) or current asthma exacerbation and/or respiratory tract infection * Subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants.) (At the discretion of the MRI Technologist/3T Manager) * In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Whole lung and lobe specific ventilation defect percent (VDP) as measured by 3He or 129Xe | 48 +/- 2 weeks post bronchial thermoplasty treatment | Change in VDP post BT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary function measurements | 48 +/- 2 weeks post bronchial thermoplasty | Change in pulmonary function post BT |
| Quality of Life questionnaires | 48 +/- 2 weeks post bronchial thermoplasty | Change in subject reported QOL post BT |
| Dyspnea Scales | 48 +/- 2 weeks post bronchial thermoplasty | Dyspnea scale score post BT |
Countries
Canada
Outcome results
None listed